Vicarious Surgical Inc. (RBOT): history, ownership, mission, how it works & makes money

A Brief History of Vicarious Surgical Inc. (RBOT)

Founding and Early Development

Vicarious Surgical Inc. was founded in 2014 by Adam Sachs and Dr. Ranjan Sinha. The company is based in Boston, Massachusetts, and focuses on developing robotic surgical systems designed to enhance minimally invasive surgery. Initial funding raised approximately $24 million during a seed round in 2018.

Technology Innovation

Vicarious Surgical is known for its unique approach to surgical robotics, integrating advanced augmented reality (AR) technology with robotic systems. The company aims to provide surgeons with enhanced visualization and precision during procedures. By 2020, Vicarious announced its proprietary surgical platform, which integrates both traditional and robotic surgical methods.

Public Offering and Market Performance

Vicarious Surgical went public on the New York Stock Exchange under the ticker symbol RBOT in July 2021. The initial public offering (IPO) raised approximately $65 million, with shares priced at $10 per share.

Financial Performance

As of Q3 2023, Vicarious Surgical reported revenues of $1.2 million, primarily from research and development of its surgical systems. The company’s operational expenses were approximately $10 million, leading to a net loss of $8.8 million for the same period.

Strategic Partnerships and Collaborations

In 2022, Vicarious Surgical entered into a collaboration with leading healthcare organizations to further develop and refine its robotic systems. The partnership aimed to accelerate clinical trials and enhance product development.

Market Position and Competitors

Vicarious Surgical operates in a competitive landscape that includes major players such as Intuitive Surgical (ISRG) and Medtronic (MDT). The global surgical robotics market was valued at approximately $4.7 billion in 2021, with a projected CAGR of 23.5% from 2022 to 2030, indicating significant growth opportunities for Vicarious Surgical.

Future Outlook

As of mid-2023, Vicarious Surgical continues to focus on expanding its product offerings and pursuing regulatory approvals. The company is optimistic about leveraging its innovative technologies to capture a larger market share in the evolving landscape of surgical robotics.

A Who Owns Vicarious Surgical Inc. (RBOT)

Company Overview

Vicarious Surgical Inc. (NASDAQ: RBOT) is a medical technology company focused on developing robot-assisted surgical systems. As of October 2023, the company's market capitalization is approximately $195 million.

Shareholder Composition

The ownership structure of Vicarious Surgical Inc. is primarily composed of institutional investors, retail investors, and company executives. The distribution of shares is critical for understanding who holds the control over the company.

Major Institutional Investors

Several key institutional investors hold significant stakes in Vicarious Surgical Inc. These include:

• BlackRock, Inc. - 12% ownership
• Vanguard Group, Inc. - 8% ownership
• Wellington Management - 5% ownership
• Franklin Templeton Investments - 4% ownership

Insider Ownership

Insider ownership plays a significant role in the governance of the company. Key executives and board members hold shares as follows:

Recent Stock Performance

As of the last trading session, Vicarious Surgical Inc. shares have experienced the following trends:

Future Outlook

Looking ahead, Vicarious Surgical Inc. is focused on expanding its market presence and enhancing its surgical offerings. Projections indicate potential revenue growth of 30% year-over-year based on current product development timelines and market entry strategies.

Conclusion

The ownership of Vicarious Surgical Inc. reflects a mixture of institutional and retail investors, with a significant portion held by company insiders. The strategic decisions made by these stakeholders will influence the company's trajectory in the competitive landscape of medical technology.

Vicarious Surgical Inc. (RBOT) Mission Statement

Corporate Mission

The mission of Vicarious Surgical Inc. (RBOT) is to revolutionize surgery by combining robotics and advanced imaging technology to provide surgeons with a minimally invasive surgical platform. This approach aims to enhance surgical precision, reduce recovery times, and ultimately improve patient outcomes.

Core Values

• Innovation: Commitment to pioneering advancements in surgical technology.
• Patient-Centricity: Focusing on patient safety and effectiveness in surgical procedures.
• Collaboration: Engaging with healthcare professionals to enhance surgical practices.
• Integrity: Upholding ethical standards in all operations and product offerings.

Market Position and Financial Overview

As of Q2 2023, Vicarious Surgical Inc. reported total revenue of $1.5 million. The company experienced a net loss of $5 million in the same quarter. The total assets stood at $28 million, while total liabilities were reported at $6 million.

Strategic Goals

• Product Development: Launching the flagship robotic surgical system in 2024.
• Market Expansion: Targeting hospitals in North America and Europe, with a projected market entry in 2025.
• Partnerships: Building strategic alliances with leading surgical centers to enhance product offerings.

Technological Advancements

Vicarious Surgical Inc. aims to integrate artificial intelligence and machine learning into their surgical systems to improve decision-making processes during surgeries. The company is committed to investing approximately $10 million over the next three years toward research and development in these areas.

Regulatory Compliance

The company adheres to stringent regulatory guidelines set by the FDA and other global health authorities to ensure the safety and efficacy of its products. Vicarious Surgical has received ISO certification, enhancing its reputation and credibility in the medical device industry.

Workforce and Culture

Vicarious Surgical Inc. employs approximately 150 staff members, focusing on creating a collaborative workplace culture that emphasizes creativity and problem-solving. The company has implemented training programs with an annual budget of $500,000 to enhance employee skills and competencies.

Future Outlook

Analysts project a compound annual growth rate (CAGR) of 25% for the robotic surgical market, which the company intends to capitalize on through its innovative technologies and strategic partnerships. The current market size for the robotic surgical systems is estimated at $6 billion, with expectations to reach $20 billion by 2028.

How Vicarious Surgical Inc. (RBOT) Works

Business Model

Vicarious Surgical Inc. operates within the robotic surgical systems market, focusing on enhancing surgical procedures through its advanced robotics technologies. As of 2023, the global surgical robotics market is projected to reach approximately $21 billion by 2026, growing at a CAGR of over 20%.

Core Technology

The company utilizes a unique robotic platform that combines human dexterity with robotic precision. The proprietary system includes:

• Miniaturized robotic instruments
• 3D visualization
• Software for enhanced surgical control

Recent Financial Performance

Vicarious Surgical reported financial results for Q2 2023, showing:

Market Expansion Strategies

To enhance its market presence, Vicarious Surgical is pursuing several strategies:

• Partnerships with healthcare institutions
• Investment in R&D for advanced technologies
• Targeting emerging markets

Regulatory Approval

As of 2023, Vicarious Surgical has received FDA clearance for its robotic-assisted surgical system, which allows for minimally invasive procedures.

Competitive Landscape

Vicarious Surgical competes with major players in the industry, including:

• Intuitive Surgical (ISRG)
• Medtronic (MDT)
• Smith & Nephew (SNOW)

Research and Development Investment

The company allocated approximately $4.2 million to R&D in Q2 2023, indicating a strong commitment to innovation.

Future Outlook

Analysts predict significant growth for Vicarious Surgical, estimating a revenue target of $15 million by 2025 driven by increased adoption of surgical robotics.

Share Performance

As of October 2023, the stock price for Vicarious Surgical (RBOT) is approximately $4.50, with a market capitalization of around $350 million.

Key Milestones

Significant milestones achieved by Vicarious Surgical include:

• FDA clearance in June 2023
• Successful initial public offering (IPO) in 2021
• Partnership with major hospitals for clinical trials

How Vicarious Surgical Inc. (RBOT) Makes Money

Revenue Streams

Vicarious Surgical Inc. generates revenue primarily through the development and commercialization of robotic surgical systems. Their business model focuses on the following key revenue streams:

• Sales of robotic surgical systems
• Service and maintenance contracts
• Consumables and accessories used in robotic surgeries

Sales of Robotic Surgical Systems

The company markets its flagship product, the Vicarious Surgical System, which is designed to enhance surgical precision and reduce the invasiveness of traditional surgical procedures. As of Q3 2023, Vicarious Surgical reported the pricing for their systems at approximately $1.5 million per unit.

Service and Maintenance Contracts

Once the surgical systems are sold, Vicarious Surgical offers maintenance and service contracts, which typically cost around $150,000 per year. This provides a recurring revenue stream that is crucial for ongoing profitability.

Consumables and Accessories

The company also generates significant revenue through the sale of consumables required for each surgery. The average cost of consumables per procedure is estimated to be around $2,000.

Market Analysis

The global robotic surgery market was valued at approximately $4.3 billion in 2022 and is expected to reach $11.4 billion by 2029, growing at a CAGR of 14.7%.

Financial Performance

For the fiscal year ending December 31, 2022, Vicarious Surgical reported the following financial data:

Partnerships and Collaborations

Vicarious Surgical has strategic partnerships with various healthcare institutions and technology firms to enhance their product offerings. Collaborations with leading hospitals can lead to significant long-term contracts and increased sales volume.

Future Projections

The company aims to expand its market share by introducing innovative features and improving its technology. Revenue projections for the next five years anticipate reaching as high as $100 million by 2028, assuming successful product adoption and market penetration.

Investment Activities

Vicarious Surgical went public in 2020, raising about $120 million in initial public offerings to fund product development and marketing initiatives.

Conclusion on Financial Outlook

Current financial health indicators suggest a robust investment into R&D, with allocations projected to be around $15 million annually to support technological advancements and product improvements.